1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Human Growth Hormone Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Human Growth Hormone Market Analysis and Forecast, 2023–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Mergers & Acquisitions
5.3. COVID-19 Pandemic Impact on Industry
6. Global Human Growth Hormone Market Analysis and Forecast, by Route of Administration
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Route of Administration, 2023–2031
6.3.1. Intravenous
6.3.2. Subcutaneous
6.3.3. Intramuscular
6.3.4. Oral
6.4. Market Attractiveness Analysis, by Route of Administration
7. Global Human Growth Hormone Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2023–2031
7.3.1. Hospital Pharmacy
7.3.2. Online Pharmacy
7.3.3. Retail Pharmacy
7.3.4. Clinics
7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Human Growth Hormone Market Analysis and Forecast, by Indication
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Indication, 2023–2031
8.3.1. Growth Hormone Deficiency
8.3.2. Turner Syndrome
8.3.3. Idiopathic Short Stature
8.3.4. Prader-Willi Syndrome
8.3.5. Other Indications
8.4. Market Attractiveness Analysis, by Indication
9. Global Human Growth Hormone Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2023–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Human Growth Hormone Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Route of Administration, 2023–2031
10.3.1. Intravenous
10.3.2. Subcutaneous
10.3.3. Intramuscular
10.3.4. Oral
10.4. Market Value Forecast, by Distribution Channel, 2023–2031
10.4.1. Hospital Pharmacy
10.4.2. Online Pharmacy
10.4.3. Retail Pharmacy
10.4.4. Clinics
10.5. Market Value Forecast, by Indication, 2023–2031
10.5.1. Growth Hormone Deficiency
10.5.2. Turner Syndrome
10.5.3. Idiopathic Short Stature
10.5.4. Prader-Willi Syndrome
10.5.5. Other Indications
10.6. Market Value Forecast, by Country, 2023–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Route of Administration
10.7.2. By Distribution Channel
10.7.3. By Indication
10.7.4. By Country
11. Europe Human Growth Hormone Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Route of Administration, 2023–2031
11.3.1. Intravenous
11.3.2. Subcutaneous
11.3.3. Intramuscular
11.3.4. Oral
11.4. Market Value Forecast, by Distribution Channel, 2023–2031
11.4.1. Hospital Pharmacy
11.4.2. Online Pharmacy
11.4.3. Retail Pharmacy
11.4.4. Clinics
11.5. Market Value Forecast, by Indication, 2023–2031
11.5.1. Growth Hormone Deficiency
11.5.2. Turner Syndrome
11.5.3. Idiopathic Short Stature
11.5.4. Prader-Willi Syndrome
11.5.5. Other Indications
11.6. Market Value Forecast, by Country/Sub-region, 2023–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Route of Administration
11.7.2. By Distribution Channel
11.7.3. By Indication
11.7.4. By Country/Sub-region
12. Asia Pacific Human Growth Hormone Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Route of Administration, 2023–2031
12.3.1. Intravenous
12.3.2. Subcutaneous
12.3.3. Intramuscular
12.3.4. Oral
12.4. Market Value Forecast, by Distribution Channel, 2023–2031
12.4.1. Hospital Pharmacy
12.4.2. Online Pharmacy
12.4.3. Retail Pharmacy
12.4.4. Clinics
12.5. Market Value Forecast, by Indication, 2023–2031
12.5.1. Growth Hormone Deficiency
12.5.2. Turner Syndrome
12.5.3. Idiopathic Short Stature
12.5.4. Prader-Willi Syndrome
12.5.5. Other Indications
12.6. Market Value Forecast, by Country/Sub-region, 2023–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Route of Administration
12.7.2. By Distribution Channel
12.7.3. By Indication
12.7.4. By Country/Sub-region
13. Latin America Human Growth Hormone Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Route of Administration, 2023–2031
13.3.1. Intravenous
13.3.2. Subcutaneous
13.3.3. Intramuscular
13.3.4. Oral
13.4. Market Value Forecast, by Distribution Channel, 2023–2031
13.4.1. Hospital Pharmacy
13.4.2. Online Pharmacy
13.4.3. Retail Pharmacy
13.4.4. Clinics
13.5. Market Value Forecast, by Indication, 2023–2031
13.5.1. Growth Hormone Deficiency
13.5.2. Turner Syndrome
13.5.3. Idiopathic Short Stature
13.5.4. Prader-Willi Syndrome
13.5.5. Other Indications
13.6. Market Value Forecast, by Country/Sub-region, 2023–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Route of Administration
13.7.2. By Distribution Channel
13.7.3. By Indication
13.7.4. By Country/Sub-region
14. Middle East & Africa Human Growth Hormone Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Route of Administration, 2023–2031
14.3.1. Intravenous
14.3.2. Subcutaneous
14.3.3. Intramuscular
14.3.4. Oral
14.4. Market Value Forecast, by Distribution Channel, 2023–2031
14.4.1. Hospital Pharmacy
14.4.2. Online Pharmacy
14.4.3. Retail Pharmacy
14.4.4. Clinics
14.5. Market Value Forecast, by Indication, 2023–2031
14.5.1. Growth Hormone Deficiency
14.5.2. Turner Syndrome
14.5.3. Idiopathic Short Stature
14.5.4. Prader-Willi Syndrome
14.5.5. Other Indications
14.6. Market Value Forecast, by Country/Sub-region, 2023–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Route of Administration
14.7.2. By Distribution Channel
14.7.3. By Indication
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Merck KGaA
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Eli Lilly and Company
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Pfizer Inc
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Novo Nordisk A/S
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Ipsen SA
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Roche Holdings, Inc
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Anhui Anke Biotechnology (Group) Co., Ltd.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Biopartners GmbH
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. GeneScience Pharmaceuticals Co., Ltd.
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Novartis AG
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
